EntryPoint Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

EntryPoint Capital’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$299K	Buy	5,219 +1,672	+47%	+$91.6K	0.07%	555
2026 Q1	$200K	Sell	3,547 -3,482	-50%	-$203K	0.06%	645
2025 Q4	$418K	Sell	7,029 -4,544	-39%	-$247K	0.16%	234
2025 Q3	$627K	Buy	11,573 +6,911	+148%	+$395K	0.24%	99
2025 Q2	$256K	Buy	+4,662	New	+$275K	0.13%	361
2024 Q4	–	Sell	-4,526	Closed	-$318K	–	736
2024 Q3	$318K	Sell	4,526 -105	-2%	-$8.78K	0.18%	226
2024 Q2	$381K	Buy	4,631 +3,414	+281%	+$284K	0.18%	96
2024 Q1	$106K	Buy	+1,217	New	+$109K	0.1%	387

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

EntryPoint Capital's BMRN Position: Q2 2026 in Review

EntryPoint Capital increased its BioMarin Pharmaceuticals (BMRN) stake by 47% in Q2 2026, buying an estimated $91.6K and bringing the position to 5,219 shares worth $299K. The position accounts for 0.07% of the portfolio, ranked #555.

EntryPoint Capital first reported a position in BMRN in Q1 2024 and has held it in 8 quarters since. The position peaked at $627K in Q3 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

EntryPoint Capital held 5,219 shares of BioMarin Pharmaceuticals worth $299K as of Q2 2026.
EntryPoint Capital bought 1,672 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $91.6K.
BioMarin Pharmaceuticals made up 0.07% of EntryPoint Capital's portfolio in Q2 2026, its #555 holding.
EntryPoint Capital first reported a position in BioMarin Pharmaceuticals in Q1 2024 and has held it in 8 quarters since.
EntryPoint Capital's BioMarin Pharmaceuticals position peaked at $627K in Q3 2025.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.